Lucy Enriquez's GLP-1 weight loss claims fact-checked

What did @lucyenriquez_ actually say?

She kept it short: "Go back and watch my videos. In three months, I lost 28 pounds. I feel amazing." She's calling semaglutide "the skinny injection" and telling viewers flat-out to get on it. No caveats, no mention of side effects, no acknowledgment that results vary. Just a personal win presented as a universal green light.

To be fair, she's sharing her own experience, not posing as a doctor. But with 138,600 views and a caption that says "Skinny Minnie," the framing matters. This reads less like a personal diary entry and more like an unqualified endorsement of a prescription medication that carries real risks and requires medical oversight.

Does the science back this up?

The 28-pound figure in three months is on the high end of what clinical trials show, but it's not impossible. The evidence on semaglutide is genuinely strong, so she's not making things up.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that adults on 2.4mg weekly semaglutide lost an average of 14.9% of body weight over 68 weeks. In the first 12 weeks, weight loss is typically in the 4-8% range for most participants. For someone starting at a higher body weight, 28 pounds in 3 months is mathematically plausible but sits well above the average. The SURMOUNT-1 trial for tirzepatide (Jastreboff et al., 2022, NEJM) showed even larger losses over time, but again, averages are averages. Individual results depend on starting weight, diet, activity level, dosing schedule, and adherence. Her result is real for her. It is not a promise to anyone else.

What did they get wrong (or right)?

She got the core fact right: semaglutide does produce meaningful weight loss for many people. The clinical data on that is not in dispute. Where she goes wrong is the implied universality of her result and the absence of any context about what this drug actually involves.

Semaglutide is a prescription GLP-1 receptor agonist. It can cause nausea, vomiting, gastroparesis, pancreatitis, and in patients with a personal or family history of medullary thyroid carcinoma, it carries a boxed warning. The FDA label is not a formality. Telling a mass audience to "do it" without any of that context is irresponsible, even if unintentionally so. She also uses the informal name "semi-glutide" rather than semaglutide, which is a minor point but signals this is casual advice, not informed guidance. There's also no mention of whether she's using brand-name Wegovy, Ozempic prescribed off-label, or a compounded version, which are not clinically equivalent products.

What should you actually know?

Semaglutide works. The evidence base is solid and the weight loss outcomes in clinical trials are among the most consistent seen in obesity pharmacotherapy in decades. But "it worked for me, do it" skips several steps that actually matter.

First, candidacy: semaglutide is FDA-approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. Second, access: it requires a prescription and, in many cases, prior authorization. Third, compounded versions are not FDA-approved and are not the same as brand-name Wegovy or Ozempic. Fourth, weight regain after stopping is well-documented. A 2022 study (Wilding et al., Diabetes, Obesity and Metabolism) found participants regained about two-thirds of lost weight within a year of stopping. This is a long-term treatment decision, not a three-month fix. A licensed clinician needs to be part of that conversation.